Beijing Health (Holdings) Limited (2389) AI Stock Analysis

• Market Cap: HK$515.00M
• Dividend Yield: N/A
• Average Volume (3M): 1.89M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.09
• Revenue Growth: 12.99%
• EPS Growth: 13.02%
• Country: HK
• Employees: 179
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): >-0.01
• Shares Outstanding: 6,058,772,000
• 10 Day Avg. Volume: 1,773,600
• 30 Day Avg. Volume: 1,892,800
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score reflects significant financial challenges, with declining revenues and persistent losses being the most impactful factors. Technical analysis shows mixed signals, with some potential for improvement. Valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call data and corporate events limits additional insights.

Beijing Health (Holdings) Limited Business Overview & Revenue Model

Company Description

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People's Republic of China. The company also engages in owning and developing general health industrial park and incubator projects; the sports-related businesses, including construction of stadiums and winter theme parks; and the fund investment business in the field of the biotechnology, pharmaceutical, medical services, and medical travel. In addition, the company offers investment management consulting, and medical and logistic related property development services; and trades in geriatric related furniture. As of December 31, 2021, it operated 5 geriatric care institutions with a total of 1,055 beds, including 734 beds for medical care services in 3 medical institutions. The company was formerly known as Beijing Enterprises Medical and Health Industry Group Limited and changed its name to Beijing Health (Holdings) Limited in June 2021. Beijing Health (Holdings) Limited was founded in 1995 and is headquartered in Cheung Sha Wan, Hong Kong.

How the Company Makes Money

Beijing Health (Holdings) Limited generates revenue through the sale of its healthcare products and services. Its primary revenue streams include the manufacturing and distribution of pharmaceuticals and traditional Chinese medicine products. Additionally, the company provides healthcare services through its clinics and wellness centers, which contribute to its earnings. Partnerships with hospitals, healthcare providers, and research institutions enhance the company's product offerings and expand its market reach, further driving revenue growth.

Beijing Health (Holdings) Limited Financial Statement Overview

Summary

Beijing Health (Holdings) Limited faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong equity position and low leverage, the company struggles with negative cash flows and operational inefficiencies. The financial outlook remains uncertain, with a need for strategic improvements to stabilize and enhance financial performance.

Income Statement

The company has faced declining revenue over the past few years, with a notable decrease from 203.8M in 2021 to 149.9M in 2024. Gross profit margin has been inconsistent, with a recent drop to 23.8% in 2024. Net profit margin remains negative, indicating ongoing losses, with a net income of -116.2M in 2024. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The balance sheet shows a strong equity base with a debt-to-equity ratio of 0.003 in 2024, indicating low leverage. However, the equity ratio has slightly decreased to 88.0% in 2024 from 86.6% in 2023. Return on equity remains negative due to persistent losses. The company maintains a healthy cash position, with cash and equivalents of 211.1M in 2024.

Cash Flow

Operating cash flow remains negative, at -35.6M in 2024, indicating cash flow challenges. Free cash flow has also been negative, with a slight improvement from -45.1M in 2023 to -42.2M in 2024. The free cash flow to net income ratio is negative, reflecting difficulties in generating cash from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	149.94M	140.35M	166.48M	203.78M	149.89M
Gross Profit	35.68M	38.47M	21.44M	46.99M	168.00K
EBITDA	-97.47M	-44.19M	-75.25M	-10.37M	-122.87M
Net Income	-116.22M	-61.88M	-97.70M	-39.41M	-185.32M
Balance Sheet
Total Assets	1.95B	2.18B	2.42B	2.84B	2.81B
Cash, Cash Equivalents and Short-Term Investments	211.08M	335.96M	440.76M	496.30M	504.63M
Total Debt	5.65M	4.89M	32.75M	48.37M	41.64M
Total Liabilities	209.74M	223.82M	271.77M	341.34M	317.57M
Stockholders Equity	1.72B	1.89B	2.04B	2.29B	2.28B
Cash Flow
Free Cash Flow	-42.20M	-45.10M	-12.34M	406.00K	17.02M
Operating Cash Flow	-35.56M	-43.72M	-11.19M	1.99M	26.73M
Investing Cash Flow	-33.80M	74.76M	-4.73M	-227.83M	122.22M
Financing Cash Flow	-5.28M	-68.40M	-16.27M	-20.46M	-83.56M

Beijing Health (Holdings) Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2389, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.01 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2389.

Beijing Health (Holdings) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$384.46M	12.06	―	7.08%	-2.88%	-21.65%
3689	71 Outperform	HK$662.10M	8.02	1.07%	8.08%	0.47%	50.46%
1518	64 Neutral	HK$341.67M	-7.31	8.55%	3.16%	-21.31%	-149.92%
2189	60 Neutral	HK$440.00M	20.09	5.01%	4.55%	16.87%	-65.89%
3869	48 Neutral	HK$950.77M	6.54	―	―	2.30%	―
2389	47 Neutral	HK$515.00M	―	-5.09%	―	12.99%	13.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Beijing Health (Holdings) Limited Corporate Events

Beijing Health Reports Reduced Losses in 2025 Interim Results

Beijing Health (Holdings) Limited reported its unaudited interim results for the six months ending June 30, 2025, showing a reduction in net loss compared to the same period in 2024. Despite a slight increase in revenue, the company experienced a comprehensive loss, although it managed to improve its gross profit and other income. The financial results reflect ongoing challenges in the market but also indicate some positive trends in operational efficiency.

Beijing Health Expands Geriatric Care with New Project in Anhui Province

Beijing Health (Holdings) Limited announced that its subsidiary, Wuxi Beikang Hongtai Geriatric Services Limited, has successfully won the bid for the Guangde Elderly Care Service Center project in Anhui Province. This project will add 290 new beds for geriatric care, increasing the Group’s total to 2,138 beds across nine healthcare institutions. The project aligns with Anhui Province’s initiative to develop Guangde City as a healthcare hub, catering to the needs of elderly populations from major cities like Shanghai and Nanjing. This expansion strengthens the company’s position in the growing geriatric care market and enhances its service offerings in a region with significant demand.

Beijing Health Announces Board Meeting for Interim Results

Beijing Health (Holdings) Limited has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the six months ending June 30, 2025, and to consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

Beijing Health Updates Nomination Committee Terms to Enhance Board Diversity

Beijing Health (Holdings) Limited has updated the terms of reference for its Nomination Committee, effective from June 20, 2025. The committee, which includes executive and independent non-executive directors, is tasked with formulating nomination policies, reviewing board diversity, and recommending candidates for director positions. This move aims to enhance the company’s corporate strategy and ensure a diverse and skilled board, potentially impacting its governance and stakeholder engagement positively.